Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
NCT ID: NCT01949129
Last Updated: 2024-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
1800 participants
INTERVENTIONAL
2013-04-30
2030-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ALL-SCT BFM International- HSCT in Children and Adolescents With ALL
NCT01423500
Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia
NCT01423747
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
NCT01772953
Allogeneic Hematopoietic Stem Cell Transplantation
NCT00750126
HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors
NCT01509300
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The trial was initiated to investigate whether chemotherapy based conditioning could replace TBI in pediatric patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (HSCT). It was registered and approved as a prospective, randomized, controlled, open-label, international, multicenter, phase III, non-inferiority trial. Pediatric patients with acute lymphoblastic leukemia (ALL) aged ≤18 years at diagnosis and 4-21 years at HSCT in complete remission pre-HSCT, and with an HLA-compatible related (MSD) or unrelated donor (MD) were randomly assigned to myeloablative conditioning with fractionated 12 Gy TBI and etoposide versus fludarabine (Flu), thiotepa (Thio), and either busulfan (Bu) or treosulfan (Treo). The decision to use the irradiation-free conditioning or Flu/Thio/Treo or Flu/Thio/ivBu was country specific. Patients aged \< 4 years received irradiation-free conditioning. Patients with a mismatched donor (MMD) were stratified according to the donor's stem cell source (cordblood, haploidentical tx or bone marrow/peripheral blood stem cells).
The stopping rule was applied on March 31, 2019 following a suspension of random assignment in December 2018 after the chemoconditioning was proven to be significantly inferior to TBI. As a result, TBI/VP16 conditioning remains the standard for patients older than 4 years with MSD/MD, but the age limit for TBI/VP16-based conditioning may be optionally lowered to 2 years.The use of Flu/Thio/Treo or Flu/Thio/ivBu conditioning in this age group is made at centre level based on individual patient assessment. Alternatively, patients aged 0-2 years may receive Bu/VP16/Cy at the discretion of the treating physician.
The MSD/MD randomised patients remain in a follow-up to explore the impact of risk factors on the incidence of Adverse Events of Special Interest (AESIs) and on overall survival and event free survival in the entire MSD/MD cohort.
In MMD patients, event free survival (EFS) after HSCT from HLA mismatched donors using mismatched unrelated donors (MMD), mismatched cord blood or HLA haplo-identical family members is observed
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Flu/Thio/Treo
Fludarabine/Thiotepa/Treosulfan is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients with:
* MSD (matched sibling donors) or MD (matched related or unrelated donors). In addition, patients undergoing MD HSCT will receive ATG Thymo- or Grafalon.
* MMD (mismatched donors) with CB (Cord blood) or TCD (T-Cell depletion) or CD34+ selection. In addition, these patients will receive ATG Thymo- or Grafalon.
* MMD (mismatched donors) patients receiving Post TX-Cyclophosphamide
Thiotepa
2x5 mg/kg BW, 1 day
Treosulfan
14g/m² BS, 3 days
Fludarabine
30 mg/m² BS, 5 days
ATG Thymoglobulin
MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
Grafalon
MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
TBI/VP16
TBI (Total Body Irradiation) / VP16 is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients older than 48 months with:
* MSD (matched sibling donors) or MD (matched related or unrelated donors). In addition, patients undergoing MD HSCT will receive ATG Thymo- or Grafalon.
* MMD (mismatched donors) with CB (Cord blood) or TCD (T-Cell depletion) or CD34+ selection. In addition, these patients will receive ATG Thymo- or Grafalon.
* MMD (mismatched donors) patients receiving Post TX-Cyclophosphamide.
Patients aged 24-48 months may optionally receive Total Body Irradiation (TBI).
VP16
60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
TBI
2 x 2Gy/day , 3 days (total 12Gy)
ATG Thymoglobulin
MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
Grafalon
MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
Flu/Thio/ivBu
Fludarabine/Thiotepa/iV Busulfan is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients with:
* MSD (matched sibling donors) or MD (matched related or unrelated donors). In addition, patients undergoing MD HSCT will receive ATG Thymo- or Grafalon.
* MMD (mismatched donors) with CB (Cord blood) or TCD (T-Cell depletion) or CD34+ selection. In addition, these patients will receive ATG Thymo- or Grafalon.
* MMD (mismatched donors) patients receiving Post TX-Cyclophosphamide
Thiotepa
2x5 mg/kg BW, 1 day
Fludarabine
30 mg/m² BS, 5 days
Busulfan
iV, dosage according therapeutic drug monitoring, 4 days
ATG Thymoglobulin
MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
Cyclophosphamide
as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
Grafalon
MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
Bu/VP16/Cy
Busulfan/VP16/Cyclophosphamide is an alternative conditioning arm that may optionally be used for HSCT with MSD/MD and MMD graft in patients aged 0-24 months. Patients undergoing MD HSCT will also receive ATG Thymo- or Grafalon.
VP16
60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
Busulfan
iV, dosage according therapeutic drug monitoring, 4 days
Cyclophosphamide
as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VP16
60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
TBI
2 x 2Gy/day , 3 days (total 12Gy)
Thiotepa
2x5 mg/kg BW, 1 day
Treosulfan
14g/m² BS, 3 days
Fludarabine
30 mg/m² BS, 5 days
Busulfan
iV, dosage according therapeutic drug monitoring, 4 days
ATG Thymoglobulin
MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
Cyclophosphamide
as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
Grafalon
MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age at diagnosis ≤ 18 years. Age at HSCT ≤ 21 years
* indication for allogeneic HSCT
* complete remission (CR) before HSCT
* written consent of the parents (legal guardian) and, if necessary, the minor patient via "Informed Consent Form"
* no pregnancy
* no secondary malignancy
* no previous HSCT
* HSCT is performed in a study participating centre
* Non Hodgkin-Lymphoma
* the whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian
* no consent is given for saving and propagation of anonymous medical data for study reasons
* severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion (e.g. malformation syndromes, cardiac malformations, metabolic disorders)
* Karnofsky / Lansky score \< 50%
* subjects unwilling or unable to comply with the study procedures
1 Month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ALL SCTped Forum
OTHER
European Society for Blood and Marrow Transplantation
NETWORK
ALL-BFM Study Group
NETWORK
Assistance Publique - Hôpitaux de Paris
OTHER
Dutch Childhood Oncology Group
OTHER
Swiss Pediatric Oncology Group
OTHER
Australian & New Zealand Children's Haematology/Oncology Group
OTHER
St. Anna Kinderkrebsforschung
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Christina Peters
Univ.-Prof. Dr. Christina Peters
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christina Peters, Prof. MD PhD
Role: STUDY_CHAIR
St. Anna Kinderspital, Vienna, Austria
Peter Bader, Prof. MD PhD
Role: STUDY_CHAIR
Goethe University
Franco Locatelli, Prof. MD PhD
Role: STUDY_CHAIR
Ospedale Pediatrico Bambino Gesù, Rome, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Pediatria "Juan P. Garrahan" Combate de Los Pozos N°1800 CABA
Buenos Aires, , Argentina
Hospital Sor Maria Ludovica, Department Hematology Stem Cell Transplant Unit
La Plata, , Argentina
Children's Cancer Centre The Royal Children's Hospital
Melbourne, , Australia
Princess Margaret Hospital for Children
Perth, , Australia
Sydney Children's Hospital
Randwick, , Australia
Lady Cilento Children's Hospital
South Brisbane, , Australia
The Children's Hospital at Westmead Oncology Unit
Sydney, , Australia
Universitätsklinik für Kinder- und Jugendheilkunde, Abt. f. Hämato-Onkologie
Graz, , Austria
Universitätsklinik für Kinder- und Jugendheilkunde
Innsbruck, , Austria
St. Anna Children's Hospital, Vienna, Austria
Vienna, , Austria
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Minsk, , Belarus
Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)
Brussels, , Belgium
Cliniques Universitaires Saint-Luc (UCL) Hématologie et oncologie pédiatrique
Brussels, , Belgium
University Hospital Gent Pediatrische hemato-oncologie
Ghent, , Belgium
University Hospitals Leuven Kinderhemato-oncologie
Leuven, , Belgium
Centre Hospitalier Universitaire de Liège Domaine Universitaire du Sart Tilman
Liège, , Belgium
Alberta Children's Hospital Division of Pediatric Oncology
Calgary, , Canada
Montreal Children's Hospital
Montral, , Canada
CHU Sainte-Justine Hematology-Oncology Division
Montreal, , Canada
Hospital for Sick Children University of Toronto Division of Haematology/Oncology
Toronto, , Canada
BC Children's Hospital
Vancouver, , Canada
CancerCare Manitoba/University of Manitoba
Winnipeg, , Canada
Hospital Dr Luis Calvo Mackenna
Santiago, , Chile
Department of Pediatrics, UHC Zagreb
Zagreb, , Croatia
Department of Pediatric Hematology and Oncology Teaching Hospital Motol, 2nd Medical School, Charles University
Prague, , Czechia
Paediatric Stem Cell Transplant and Immune Deficiency, Dept. for children and adolescents 4072, Rigshospitalet
Copenhagen, , Denmark
Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, Univ. of Helsinki
Helsinki, , Finland
CHU Bordeaux
Bordeaux, , France
CHU Clermont-Ferrand
Clermont-Ferrand, , France
CHU Grenoble - Clinique Universitaire de Pédiatrie, Hôpital Couple Enfant
Grenoble, , France
CHRU Lille, Service d'Hématologie Pédiatrique
Lille, , France
IHOP / Lyon, Service Hématologie et d'Oncologie pédiatrique
Lyon, , France
Hopital la Timone Adulte
Marseille, , France
Hopital Arnaud de Villeneuve
Montpellier, , France
CHU Nancy - Hopital d'Enfants
Nancy, , France
CHU Nantes, Service d'onco hémato pédiatrie
Nantes, , France
Hôpital Robert Debré
Paris, , France
CHU de Rennes, Serive d'Onco-Pédiatrie
Rennes, , France
CHU de Rouen, Hopital des Enfants, Service d' Immuno-Hématologie Oncologie Pédiatrique
Rouen, , France
CHU Strasbourg, Service d'hématologie et d'oncologie pédiatrique
Strasbourg, , France
Uniklinik RWTH Aachen, Kinder- und Jugendmedizin
Aachen, , Germany
Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum
Berlin, , Germany
Universitätsklinikum Bonn, Abteilung für Pädiatrische Hämatologie und Onkologie
Bonn, , Germany
Universitätsklinikum Düsseldorf, Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immunologie
Düsseldorf, , Germany
Universitätsklinikum Erlangen, Kinder- und Jugendklinik
Erlangen, , Germany
Universitätsklinikum Essen, Klinik für Kinderheilkunde III
Essen, , Germany
Klinikum der Johann Wolfgang Goethe-Universität, Klinik für Kinder- und Jugendmedizin (KKJM)
Frankfurt am Main, , Germany
Universitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin
Freiburg im Breisgau, , Germany
Universitätsklinikum Gießen, Zentrum für Kinder- und Jugendmedizin
Giessen, , Germany
Universitätsmedizin Greifswald, Klinik und Poliklinik für Kinder- und Jugendmedizin
Greifswald, , Germany
Universitätsklinikum Halle (Saale), Universitätsklinik und Poliklinik für Kinder- und Jugendmedizin
Halle, , Germany
Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Pädiatrische Hämatologie und Onkologie
Hamburg, , Germany
Medizinische Hochschule Hannover, Zentrum Kinderheilkunde und Jugendmedizin
Hanover, , Germany
Universitätsklinikum Heidelberg, Zentrum für Kinder- und Jugendmedizin
Heidelberg, , Germany
Universitätsklinikum Jena, Sektion für Stammzelltransplantation
Jena, , Germany
UKSH - Universitätsklinikum Schleswig-Holstein, Klinik für Allgemeine Pädiatrie
Kiel, , Germany
Universitätsmedizin Leipzig, Abteilung für Pädiatrische Onkologie, Hämatologie und Hämostaseologie
Leipzig, , Germany
Klinikum der Universität München, Dr. von Haunersches Kinderspital
München, , Germany
Städt. Krankenhaus München Schwabing, Universitätskinderklinik der TU München
München, , Germany
Universitätsklinikum Münster, Klinik für Kinder- und Jugendmedizin
Münster, , Germany
Universitätsklinikum Regensburg, Klinik und Poliklinik für Kinder- und Jugendmedizin
Regensburg, , Germany
Universitätsklinik für Kinder- und Jugendmedizin Tübingen
Tübingen, , Germany
Universitätsklinikum Ulm, Klinik für Kinder- und Jugendmedizin
Ulm, , Germany
Universitäts-Kinderklinik Würzburg
Würzburg, , Germany
Saint Sophia Children's Hospital BMT Unit
Athens, , Greece
National Institute of Haematology and Infectious Disease, Hospital of Southern Pest, Paediatric Bone Marrow Transplantation Unit
Budapest, , Hungary
Rambam Medical Center
Haifa, , Israel
Schneider Children's Medical Center of Israel
Petah Tikva, , Israel
Dana Children's Hospital
Tel Aviv, , Israel
Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi di Bologna
Bologna, , Italy
Ospedale Mayer di Firenze SODc Tumori Pediatrici e TMO
Florence, , Italy
Istituto Gaslini Genova Oncoematologia Pediatrica-
Genoa, , Italy
A.O. San Gerardo di Monza Clinica Pediatrica
Monza, , Italy
A.O.R.N. Santobono Pausilipon, Dipartimento di Oncoematologia
Napoli, , Italy
Azienda Ospedaliera di Padova Oncoematologia Pediatrica
Padua, , Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, , Italy
Azienda Ospedaliero Universitaria Pisana U.O. di Oncoematologia Pediatrica A.O.
Pisa, , Italy
Ospedale Pediatrico Bambino Gesù, Sapienza, University of Rome
Rome, , Italy
Ospedale Infantile Regina Margherita SC Oncoematologia e Centro Trapianti
Torino, , Italy
University of Malaya, Department of Paediatrics
Kuala Lumpur, , Malaysia
Instituto Nacional de Peditria
Mexico City, , Mexico
Leiden University Medical Center Department of Pediatrics/BMT unit
Leiden, , Netherlands
Princess Máxima Center for Pediatric Oncology
Utrecht, , Netherlands
Starship Children's Hospital
Auckland, , New Zealand
Oslo University Hospital Rikshospitalet
Oslo, , Norway
University Hospital No.1, Collegium Medicum UMK, department of Paediatrics, Oncology, Hematology and Paediatric Transplantology
Bydgoszcz, , Poland
University Children's Hospital in Krakow, Department of Transplantation
Krakow, , Poland
Children's University Hospital, Dept. Pediatric Hematology, Oncology, and Transplantology
Lublin, , Poland
Poznan University of Medical Sciences, Department of Pediatric Onology, Hematology & HSCT
Poznan, , Poland
Cape of Hope, Wroclaw Medical University
Wroclaw, , Poland
IInsitutul Clinic Fundeni, Sectia de Transplant Medular
Bucharest, , Romania
University of Medicine and Pharmacy V. BABES, Emergency Children's Hospital LOUIS TURCANU, III. Clinic of Pediatrics , Department of Onco-hematology and Bone Marrow Transplantation
Timișoara, , Romania
King Abdullah specialists children hospital
Riyadh, , Saudi Arabia
University Children's Hospital
Bratislava, , Slovakia
University childrens' hospital, UMCL
Ljubljana, , Slovenia
Hospital Santa Creu i Sant Pau
Barcelona, , Spain
Hospital Vall d'Hebron
Barcelona, , Spain
Hospital Materno Infantil de Málaga
Málaga, , Spain
Hospital Virgen de la Arrixaca
Murcia, , Spain
Hospital Universitario Central de Asturias
Oviedo, , Spain
Queen Silvia Children's Hospital, Department of Pediatric Oncology (Avdelnig 321-322)
Gothenburg, , Sweden
Skane University Hospital, Dept. of Pediatrics, Section for Hematology and Oncology
Lund, , Sweden
Karolinska University Hospital, Department of Pediatrics
Stockholm, , Sweden
University Children's Hospital, Dept. of Women's & Children's Health Section for Pediatrics
Uppsala, , Sweden
Universitäts-Kinderspital beider Basel (UKBB)
Basel, , Switzerland
HUG Hôpitaux Universitaire de Genève
Geneva, , Switzerland
Universitäts-Kinderspital Zurich
Zurich, , Switzerland
Ankara University School of Medicine Pediatric Stem Cell Transplantation Unit
Ankara, , Turkey (Türkiye)
Gazi University School of Medicine Pediatric Stem Cell Transplantation Unit
Ankara, , Turkey (Türkiye)
Gülhane Training and Research Hospital
Ankara, , Turkey (Türkiye)
Akdeniz University School of Medicine Pediatric Stem Cell Transplantation Unit
Antalya, , Turkey (Türkiye)
Bahcesehir University School of Medicine Pediatric Stem Cell Transplantation Unit
Antalya, , Turkey (Türkiye)
Acibadem University Atakent Hospital Pediatric Stem Cell Transplantation Unit
Istanbul, , Turkey (Türkiye)
Bahcelievler Medicalpark Hospital Pediatric Stem Cell Transplantation Unit
Istanbul, , Turkey (Türkiye)
Bahcesehir University School of Medicine Pediatric Stem Cell Transplantation Unit
Istanbul, , Turkey (Türkiye)
Medipol Mega Üniversite Hastanesi
Istanbul, , Turkey (Türkiye)
Dokuzeylul University School of Medicine Pediatric Stem Cell Transplantation Unit
Izmir, , Turkey (Türkiye)
Ege University School of Medicine Pediatric Stem Cell Transplantation Unit
Izmir, , Turkey (Türkiye)
Erciyes University School of Medicine Pediatric Stem Cell Transplantation Unit
Kayseri, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
[email protected]
Role: backup
Ernest Bilic, MD PhD
Role: primary
Arjan Lankester, MD PhD
Role: primary
Role: backup
Mehmet Ertem, MD PhD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Kalwak K, Moser LM, Potschger U, Bader P, Kleinschmidt K, Meisel R, Dalle JH, Yesilipek A, Balduzzi A, Krivan G, Goussetis E, Staciuk R, Sedlacek P, Pichler H, Svec P, Gabriel M, Gungor T, Bilic E, Buechner J, Renard M, Vettenranta K, Ifversen M, Diaz-de-Heredia C, Stein J, Toporski J, Bierings M, Peters C, Ansari M, Locatelli F. Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM. Blood Adv. 2025 Feb 25;9(4):741-751. doi: 10.1182/bloodadvances.2024014548.
Bader P, Potschger U, Dalle JH, Moser LM, Balduzzi A, Ansari M, Buechner J, Gungor T, Ifversen M, Krivan G, Pichler H, Renard M, Staciuk R, Sedlacek P, Stein J, Heusel JR, Truong T, Wachowiak J, Yesilipek A, Locatelli F, Peters C. Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study. Blood Adv. 2024 Jan 23;8(2):416-428. doi: 10.1182/bloodadvances.2023010591.
Gomez SM, Varela MA, Ruiz C, Sung L. Comparable Outcomes of Matched Sibling Donor and Matched Unrelated Donor Stem Cell Transplantation in Children With Acute Leukemia in Argentina. J Pediatr Hematol Oncol. 2021 Oct 1;43(7):e1020-e1024. doi: 10.1097/MPH.0000000000002174.
Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, Shaw PJ, Staciuk R, Ifversen M, Pichler H, Vettenranta K, Svec P, Aleinikova O, Stein J, Gungor T, Toporski J, Truong TH, Diaz-de-Heredia C, Bierings M, Ariffin H, Essa M, Burkhardt B, Schultz K, Meisel R, Lankester A, Ansari M, Schrappe M; IBFM Study Group;; von Stackelberg A; IntReALL Study Group; Balduzzi A; I-BFM SCT Study Group; Corbacioglu S; EBMT Paediatric Diseases Working Party; Bader P. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2021 Feb 1;39(4):295-307. doi: 10.1200/JCO.20.02529. Epub 2020 Dec 17.
Tasian SK, Peters C. Targeted therapy or transplantation for paediatric ABL-class Ph-like acute lymphocytic leukaemia? Lancet Haematol. 2020 Dec;7(12):e858-e859. doi: 10.1016/S2352-3026(20)30369-0. No abstract available.
Choong E, Uppugunduri CRS, Marino D, Kuntzinger M, Doffey-Lazeyras F, Lo Piccolo R, Chalandon Y, Peters C, Daali Y, Ansari M. Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance. Ther Drug Monit. 2018 Feb;40(1):84-92. doi: 10.1097/FTD.0000000000000468.
Related Links
Access external resources that provide additional context or updates about the study.
St. Anna Kinderkrebsforschung
St. Anna Kinderspital
Peters C et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2021 Feb 1;39(4):295-307
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALL SCTped FORUM 2012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.